These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 27070364)

  • 1. [The results of an open prospective study of β-interferon biosimilars (an Yaroslavl' cohort)].
    Kasatkin DS; Spirin NN; Boiko AN; Stepanov IO; Spirina NN; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):68-73. PubMed ID: 27070364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
    Borets OG; Govorukhina NF; Zverev KV; Boiko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):63-67. PubMed ID: 27070363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate].
    Khabirov FA; Khaybullin TI; Granatov EV; Shakirzianova SR; Babicheva NN; Kochergina OS; Rakhmatullina EF; Akhmedova GM; Averyanova LA; Yakupov MA; Sabirov ZF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(3):18-26. PubMed ID: 29652301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
    Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
    Popova EV; Boĭko AN; Vasil'ev AV; Davydovskaia MV; Zavalishin IA; Kotov SV; Krotenkova MV; Khachanova NV; Sharanova SN; Shchur SG; Iakushina TI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):56-61. PubMed ID: 22951783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal].
    Khabirov FA; Babicheva NN; Khaĭbullin TI; Aver'ianova LA; Granatov EV; Akhmedova GM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):113-22. PubMed ID: 23235429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation].
    Bakhtiiarova KZ; Bragina OV; Vlasov IaV; Greshnova IV; Evdoshenko EP; Ivanishenkova EI; Kairbekova EI; Karnaukhova EN; Korotkevich NA; Leliukhina AV; Protasov IS; Rybina EV; Sazhnev AI; Skoromets AA; Soldatova OA; Trinitatskiĭ IuV; Fedianin AS; Chelnokova SN; Shabanova VD; Sharipova RR; Shchegol'kova EA; Iampol'skaia-Gosteva IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):39-45. PubMed ID: 25345629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis].
    Popova EV; Boyko AN; Bykova OV; Nankina IG; Batysheva TT
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):73-75. PubMed ID: 27456908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
    Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
    Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interferon-β1α therapy on multiple sclerosis based on gadolinium-enhancing or active T2 magnetic resonance imaging outcomes: a meta-analysis.
    Lu Y; Zhao J; Zhan Q
    Neurol Res; 2016 Oct; 38(10):909-15. PubMed ID: 27553873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
    Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience of using interferon Β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center].
    Borets OG; Davydovskaya MV; Demina TL; Lashch NY; Popova NF; Popova EV; Khachanova NV; Khasayeva MV; Shchur SG; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(2 Pt 2):51-56. PubMed ID: 26081337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
    Prosperini L; Mancinelli CR; De Giglio L; De Angelis F; Barletta V; Pozzilli C
    Mult Scler; 2014 Apr; 20(5):566-76. PubMed ID: 23999607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of tobacco smoking on clinical effectiveness of immunomodulatory treatment in multiple sclerosis patients].
    Jernas Ł; Piorunek T; Tokarz E; Wygladalska-Jernas H; Kozubski W; Michalak S
    Przegl Lek; 2012; 69(10):750-2. PubMed ID: 23421025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
    PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics.
    Vidal-Jordana A; Sastre-Garriga J; Pérez-Miralles F; Pareto D; Rio J; Auger C; Tintoré M; Rovira A; Montalban X
    J Neuroimaging; 2016 Sep; 26(5):532-8. PubMed ID: 26935253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3].
    Kotov SV; Kudlay DA; Lizhdvoy VY; Stashuk GA; Magomedova SB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):107-115. PubMed ID: 31156249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.